search.noResults

search.searching

note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
FOCUS BUSINESS NEWS


FOCUS BUSINESS NEWS


IPG exceeds $1 billion in annual sales


IPG Photonics has reported annual sales exceeding $1 billion in 2016, an increase of 12 per cent year-on-year. The company’s fourth quarter sales, driven by the materials processing markets, increased by 25 per cent to $280.1 million year-on-year. Strong growth was reported in China, Europe, Russia and Japan, while sales in North America were slightly up from Q4 2015. The company’s materials


processing sales saw a 24 per cent increase compared to Q4 2015. According to IPG, this is due to solid demand for cutting and micro materials processing applications. High- power fibre laser sales grew 35 per cent year-on-year, while sales of QCW lasers grew by double digits and pulsed lasers by single digits. Sales to other markets were


driven by a strong growth in telecoms, increasing by 48 per cent year-on-year, according to the company. In May 2016, IPG bought Menara Networks for $46.8 million, a provider of optical transmission modules and systems, which will allow IPG to expand its telecom product offerings. During the fourth quarter,


IPG generated $99.3 million in cash from operations and used $27 million to finance capital expenditures, compared to the annual figures totalling $292.3 million of generated cash and $127 million financing capital expenditures. The company ended the quarter with $830.6 million in cash, cash equivalents and short-term investments, representing an increase of $141.5 million from 31 December 2015. IPG expects revenue in the


range of $245-260 million for the first quarter of the year, and expects its annual revenue to grow by 10-14 per cent.


l Aim to advance biomedical sciences and neurological disease treatments


l Goal to encourage close co-operation between diverse branches of research


Laser Zentrum Hannover (LZH) has set up a nationwide network in Germany with the goal of moving optogenetics out of the research stage to a level where it can benefit society. The group will work to connect research with politics and the economy, in order to advance the biomedical sciences field and the development of treatments for neurological diseases. Optogenetics – a technology combining optics with genetic engineering – involves using light pulses to induce and observe muscle contractions, nerve impulses or certain intermediate metabolic products inside the body. The technique is often used in brain


research, to activate neurons and monitor neuronal activity. In an optogenetics article for Electro Optics, Marco Arrigoni, director of marketing at Coherent, compared the


4 Electro Optics March 2017


technique to a subway map of London. ‘Imaging is the equivalent of creating a map of all the lines. Optogenetics and signalling is the equivalent of having the subway map, plus controlling the trains and seeing where the trains go all of the time,’ he said. The goal of LZH’s new network,


called ‘Innovation Forum Optogenetics – Technologies and Potential’, is to encourage close co-operation between diverse branches of research spanning areas from molecular biology to laser physics. And, through intensive dialogue with economists, the general public and political bodies, the consortium will work to transfer knowledge from the laboratories more quickly into innovative processes and products that benefit society. The network will be established within


the framework of Germany’s Federal Ministry of Education and Research (BMBF) initiative, ‘Innovation forums for small and medium-sized enterprises (SMEs)’, which aims to encourage SMEs to generate new ideas and trendsetting applications based on research results.


@electrooptics | www.electrooptics.com


Laser Zentrum Hannover creates German optogenetics research group


vitstudio/Shutterstock.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44